Janet de Beukelaar
Overview
Explore the profile of Janet de Beukelaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
63
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Pamelen J, Rodriguez-Mogeda C, van Olst L, van der Pol S, Boon M, de Beukelaar J, et al.
Front Immunol
. 2025 Mar;
16:1514762.
PMID: 40083553
Introduction: Cladribine tablets are an effective treatment for relapsing remitting multiple sclerosis (RRMS). However, almost half of the treated patients are not free of disease activity after two years. The...
2.
Blok K, Klein Kranenbarg R, Ananth K, Engelenburg H, van den Bosch A, Giannini L, et al.
Eur J Neurol
. 2025 Feb;
32(2):e70052.
PMID: 39907163
Background: Relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory...
3.
Coerver E, Fung W, de Beukelaar J, Bouvy W, Canta L, Gerlach O, et al.
JAMA Neurol
. 2024 Dec;
82(2):123-131.
PMID: 39652340
Importance: Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden,...
4.
van Puijfelik F, Blok K, Klein Kranenbarg R, Rip J, de Beukelaar J, Wierenga-Wolf A, et al.
Brain Commun
. 2024 Feb;
6(1):fcae021.
PMID: 38385000
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however, subpopulations of CD4 and CD8 T cells in peripheral blood...
5.
van den Berg R, Blok K, Tebayna N, Dijk M, van Rosmalen J, de Beukelaar J
Int J MS Care
. 2024 Jan;
26(1):30-35.
PMID: 38213677
Background: Questions asked by patients with primary progressive multiple sclerosis (PPMS) during patient-initiated MS nurse consultations may contain salient information that can help health care providers understand their needs, which,...
6.
Blok K, van Rosmalen J, Tebayna N, Smolders J, Wokke B, de Beukelaar J
Front Neurol
. 2023 Nov;
14:1277477.
PMID: 38020591
Background: Disease activity in multiple sclerosis (MS) is defined as presence of relapses, gadolinium enhancing lesions and/or new or enlarging lesions on MRI. It is associated with efficacy of immunomodulating...
7.
Blok K, Smolders J, van Rosmalen J, Martins Jarnalo C, Wokke B, de Beukelaar J
Eur J Neurol
. 2023 Aug;
30(12):3799-3808.
PMID: 37578087
Background And Purpose: Despite the 2017 revisions to the McDonald criteria, diagnosing primary progressive multiple sclerosis (PPMS) remains challenging. To improve clinical practice, the aim was to identify frequent diagnostic...
8.
de Graaf M, de Beukelaar J, Bergsma J, Kraan J, van den Bent M, Klimek M, et al.
J Neuroimmunol
. 2008 Mar;
195(1-2):164-70.
PMID: 18358542
In paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS) an important role for cellular immunity is hypothesized. We characterized the cerebrospinal fluid (CSF) pleocytosis in Hu-PNS patients by assessing the major...
9.
Shamsili S, de Beukelaar J, Gratama J, Hooijkaas H, van den Bent M, van t Veer M, et al.
J Neurol
. 2006 Jan;
253(1):16-20.
PMID: 16444604
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore...